Posted on 23/11/2009 in Pharmaceutical Company Product News Pfizer revealed this week that the Food and Drug Administration (FDA) has approved Geodon (ziprasidone) for use in patients with bipolar I disorder.
The drug is to be used as an adjunct to lithium and valproate in adults.
This approval comes following clinical trials which showed that Geodon is effective and well-tolerated in the long-term controlling of the disorder.
Geodon, with a combination of either lithium or valproate, was found to be a more effective treatment than placebo plus lithium or valproate in prolonging the time between mood episodes.
Charles Bowden, clinical professor of psychiatry and pharmacology, University of Texas Health Science Center, stated: "The FDA approval of Geodon provides an additional treatment option for patients with bipolar disorder, who require maintenance therapy to keep the symptoms of the disease under control."
Meanwhile, earlier this month, Pfizer announced the establishment of its new global research and development network, which will see it develop new areas of expertise following its recent merger with Wyeth.Other news stories from 23/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
